Volumepriceanalysis
Bitcoin: Likely to head to 45,000This evening price finally broke through the low of 51,300
after being in a squeeze to the downside. That squeeze can
be better seen on an hourly chart. Click link for pic of that.
www.screencast.com
The past few days including today were bearish bars but
"normal" volume bars. The buyers are not stepping back in
yet. They have tried to hold the line for the past few days
but it looks like the sellers are going to push prices lower.
It is possible that we could have a failed breakout of the
51,300 level but it would have to happen fairly quickly
within the next 24-48 hours in my opinion.
The next support level to be hit is around 45,000 from
Feb 28th.
We'll see what tomorow's bar brings!
Note: I am not long Bitcoin.
Bitcoin: Low Volume Selling, Buyers still in controlBuyers are really trying to push price higher but are
struggling to push through the 59,500-60,000 level.
On the daily chart, April 3rd and April 4th were low volume
sell bars (yellow bars on chart). Price then broke above the high of the
April 4th low volume selling bar which was an indication that
sellers still do not have control. Price hit resistance and is now coming
down a little.
They are trying to sell again and break through the 21 day EMA but even
if they do, there is no indication yet that buyers are getting out of their
long positions in substantial numbers.
I am currently long Bitcoin.
$BLFDF Sky Highhh Blockchain Foundry Inc. develops and commercializes blockchain-based business solutions in the Americas, the Caribbean, and Europe. Its solutions include Syscoin Spark Wallet that allows clients to have their custom wallet based on their syscoin platform token; Syscoin Price Peg Server, which allow non-coders to create and configure its own price peg server; and Blockmarket suite, a marketplace platform. The company also provides consulting services to corporate clients seeking to incorporate blockchain technology into their business. Blockchain Foundry Inc. was founded in 2016 and is headquartered in Toronto, Canada.
$NSPR InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.
$TNXPTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.
$CLSN PT 3-3.60 and higherCelsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
AUDCAD Trade IdeaWe recently broke the Daily resistance at 0.96500, on this Leg we mostly accumulated orders at 0.96500,
so if we come back to test this now turned support, i will look for confirmation that this level holds to enter a long position,
my first targets will be the -0.272 extension which lines up with the 0.97500 psychological resistance,
my overall target will be the -0.618 fib extension which lines up with the next daily resistance at 0.97912
ETH short term trading setup!ETH/USD just formed a nice short opportunity. The 4H bar closed below the upper side of the trading base ($334-$395), breaking October's POC. If the price will be able to stay below the level of $395, then we would probably see the downward movement toward the bottom of the trading base. At the bottom of the trading base, we can see a nice accumulation towards which the price will aim to go.
Trading Setup.
Entry: $392-$396
Stop-Loss: $406-$408
Take Profit: $345-$348
Risk-reward: 4:1
Overall, ETH is still in the upper trend from march 2020, therefore in the macro picture, this is counter-trend trade.
TechnoFundamental Analysis for IDX-WOOD IDX:WOOD is showing a clear sign of trend reversal.
Technical :
After making consistent higher low and higher high, IDX:WOOD is reaching a new high and hit EMA 90 (Sell Area 1) .
The price would retrace for a while and then hopefully it would bounce back higher to sell area 2.
Fundamental :
Sell Area 2 is similar with the stock's intrinsic value (around 640).
Good Luck!
GDX Volume Spread AnalysisAMEX:GDX
looking at lower demand during rally due to a lack of volume, showing that smart money is not interested in propping the market up in the shorter term. as prices approach key supply zone.
1)Possible consolidation and profit taking happening
2)Renewed strength to break out of that level
For now just no action and observing the market.
WFC Volume Spread AnalysisNYSE:WFC
Potential smart money involvement in buying at this key level 23. As back in 2011 reference a strong support level of instituitional buying.
however the stock rally remain weak, signalling that there might still be more Supply > Demand. waiting for a retest on 23 level with lower volume to enter a buy trade setup.